The raison d'etre behind PanGenetics B.V. is to arbitrage the value differential between preclinical antibodies and antibodies with human proof-of-principle data. With three in-house MAbs and two that it has in-licensed in the past two weeks, the company will now get a chance to make its case.
PanGenetics has followed a winding path to reach this point. Founded in 1995, the company originally pursued more traditional antibody discovery and development, but was then acquired and later spun out in 2003 as an empty shell from Tanox Inc. (TNOX, Houston, Texas).
After exploring different strategies, the company was restarted in July 2005 by Index